Growth Demonstrates the Company’s Commitment to Advancing Myopia Management as the
Standard of Care
ROCHESTER, N.Y., November 4, 2024—CooperVision is reinforcing its leadership in U.S. myopia care by more than doubling its myopia sales team. This expansion establishes a new industry benchmark and underscores the company’s ongoing efforts to advance the field. At Academy 2024 in Indianapolis, CooperVision will showcase this enhanced commitment alongside the latest innovations and collaborations shaping the future of children's eye health.
“Our expanded group of myopia experts are dedicated to offering nationwide support to practices with comprehensive solutions, including MiSight® 1 day*, and Paragon CRT®,†§” said Tony Sommer, General Manager, Myopia & Specialty Americas, CooperVision. “This investment extends beyond our team—it's a pledge to elevate myopia management as the standard of care. With over 150,000 children worldwide wearing MiSight® 1 day soft contact lenses,*1 our determination to expand this impact has never been stronger.”
The myopia sales team plays an essential role in supporting CooperVision’s entire myopia management portfolio, offering personalized guidance and expertise to help eye care professionals (ECPs) successfully implement these innovative solutions. Their help and support empower more ECPs to tackle myopia and deliver optimal care for their young patients.
At Academy 2024, CooperVision will feature its interactive "CooperVision Elementary" booth, where attendees can experience a typical school day through the eyes of a child with myopia. The company will also present new myopia management research, featuring studies on the effectiveness of MiSight® 1 day, orthokeratology, clinical practice trends, and the real-world myopia control results of these approaches.
“We're fully committed to investing the necessary resources to drive meaningful change, particularly when it comes to children’s eye health. We’ll continue pushing forward to create a lasting positive impact for children with myopia,” added Sommer.
For more information about Academy 2024, visit https://aaopt.org/meetings/academy-2024-indianapolis/ or stop by CooperVision’s booth #808.
###
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† U.S. Indications for Use: Rigid Gas Permeable Paragon CRT® Contact Lenses (paflufocon B), Paragon CRT® 100 Contact Lenses (paflufocon D) and Paragon CRT Dual Axis® Contact Lenses (paflufocon D) for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in non-diseased eyes. The lenses are indicated for overnight wear in a Corneal Refractive Therapy fitting program for the temporary reduction of myopia up to 6.00 diopters in eyes with astigmatism up to 1.75 diopters. The lenses may be disinfected using only a chemical disinfection system.
§ FDA Approved to temporarily correct vision overnight.
Reference:
1. CooperVision, data on file 2024. Internal global wearer modeling estimates for the 12-month period of May 2023 to April 2024.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week, and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, visit www.coopercos.com
Media Contact
Laura DiCaprio, Senior Counselor
McDougall Communications for CooperVision
Laura@mcdougallpr.com or +1-585-434-2153